ArticleFrontiers in endocrinology2025
Declining insulin sensitivity is a key pathological contributor to dysglycemia: a longitudinal validation study in the Korean genome and epidemiology study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The role of worsening insulin resistance (IR) in type 2 diabetes (T2D) progression among lean individuals is not well understood. We examined whether declining insulin sensitivity (IS), independent of beta-cell function (BCF), is associated with diabetes progression. Methods: In a 10-year longitudinal Korean cohort with normal glucose tolerance (N = 2,810; age 50 ± 8y; BMI 24.1 ± 2.8 kg/m²), participants underwent biannual oral glucose tolerance tests. Longitudinal changes in IS, BCF, BMI, and fat mass were evaluated. Participants were stratified by baseline BCF (low/high), diabetes progression status (non-progressors [Non-p], progressors to prediabetes [PreDM-p], or T2D [T2D-p] over time), and degree of IS decline (large/small). Results: Both T2D-p and PreDM-p showed greater IS decline than Non-p. At baseline, PreDM-p had IS comparable to T2D-p, but T2D-p declined more steeply. T2D-p and PreDM-p also had lower BCF at baseline, which remained low. Across baseline BCF groups (high/low), greater IS decline was consistently associated with higher risk of progression (all P<0.001). The effect size of IS decline exceeded that of BCF deterioration. Conclusions: Declining IS, independent of BCF, is associated with progression to T2D in lean Koreans. Preserving IS through lifestyle interventions is crucial for diabetes prevention, particularly in those with low BCF. Insulin resistance, β-cell function, disposition index, oral glucose tolerance test, body mass index.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.